NEW YORK (GenomeWeb News) – C2N Diagnostics today announced a research and supplier agreement with Cambridge Isotope Laboratories to provide C2N access to large quantities of highly enriched stable isotopes.

C2N uses the isotopes for its Stable Isotope Labeling Kinetic (SILK)-based biomarkers, which it said has the potential for use in the early detection of Alzheimer's well before clinical symptoms are evident. They also show promise as measurement tools for determining treatment response in preclinical and clinical drug studies, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.